Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
The company will also share results in two additional posters for deuruxolitinib
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Subscribe To Our Newsletter & Stay Updated
